Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bruix, Jordi
ABC-HCC, NCT04803994 / 2020-004210-35: The Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma	Recruiting	3	434	Europe, Japan	Atezolizumab, Tecentriq, Bevacizumab, Avastin, TACE, transarterial chemoembolization	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, F. Hoffmann-La Roche Ltd	Hepatocellular Carcinoma	07/27	07/27
SIRCCA, NCT02807181: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma	Completed	2/3	89	Europe, US, RoW	Cisplatin-gemcitabine, CIS-GEM, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)	Sirtex Medical	Intrahepatic Cholangiocarcinoma	10/22	10/22
LT for iCCA, NCT02878473: Liver Transplantation for Early Intrahepatic Cholangiocarcinoma	Terminated	2	2	Canada	Deceased donor Liver Transplantation	University Health Network, Toronto	Intrahepatic Cholangiocarcinoma	12/24	12/24
LLarch, Neus
No trials found